- Home
- WNW vs NRXS Comparison
WNW vs NRXS Comparison
Compare WNW & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- NRXS
- Stock Information
- Founded
- WNW 2015
- NRXS 2011
- Country
- WNW China
- NRXS United States
- Employees
- WNW N/A
- NRXS N/A
- Industry
- WNW Catalog/Specialty Distribution
- NRXS
- Sector
- WNW Consumer Discretionary
- NRXS
- Exchange
- WNW Nasdaq
- NRXS Nasdaq
- Market Cap
- WNW 26.6M
- NRXS 25.8M
- IPO Year
- WNW 2020
- NRXS 2023
- Fundamental
- Price
- WNW $1.58
- NRXS $2.58
- Analyst Decision
- WNW
- NRXS Strong Buy
- Analyst Count
- WNW 0
- NRXS 1
- Target Price
- WNW N/A
- NRXS $7.00
- AVG Volume (30 Days)
- WNW 15.0K
- NRXS 1.1M
- Earning Date
- WNW 12-04-2025
- NRXS 11-11-2025
- Dividend Yield
- WNW N/A
- NRXS N/A
- EPS Growth
- WNW N/A
- NRXS N/A
- EPS
- WNW 0.26
- NRXS N/A
- Revenue
- WNW $2,550,178.00
- NRXS $3,217,531.00
- Revenue This Year
- WNW N/A
- NRXS $50.75
- Revenue Next Year
- WNW N/A
- NRXS $130.50
- P/E Ratio
- WNW $6.32
- NRXS N/A
- Revenue Growth
- WNW N/A
- NRXS 41.93
- 52 Week Low
- WNW $0.95
- NRXS $1.33
- 52 Week High
- WNW $70.00
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- WNW 37.83
- NRXS 38.37
- Support Level
- WNW $1.45
- NRXS $2.52
- Resistance Level
- WNW $1.77
- NRXS $2.70
- Average True Range (ATR)
- WNW 0.14
- NRXS 0.26
- MACD
- WNW -0.02
- NRXS -0.11
- Stochastic Oscillator
- WNW 26.50
- NRXS 12.31
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).